Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Autoimmun Rev. 2008 May;7(5):391-7. doi: 10.1016/j.autrev.2008.03.004. Epub 2008 Apr 9.

Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.

Author information

  • 1Chemical Immunology Research Center, University of Texas Houston Medical School, Houston, TX 77030, USA.


Immunoglobulins (Igs) that bind amyloid beta peptide (Abeta) are under clinical trials for immunotherapy of Alzheimer disease (AD). We have identified IgMs and recombinant Ig fragments that hydrolyze Abeta. Hydrolysis of peripheral Abeta by the IgMs may induce increased Abeta release from the brain. The catalytic IgMs are increased in AD patients, presumably reflecting a protective autoimmune response. Reduced Abeta aggregation and neurotoxicity attributable to the catalytic function were evident. These findings provide a foundation for development of catalytic Igs for AD immunotherapy.

[PubMed - indexed for MEDLINE]
Free PMC Article

Images from this publication.See all images (1)Free text

Fig 1
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk